aluates Reports

$ 0.0

Automative

Global Exosome Therapeutics and Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: November 2025

Report Code: QYRE-Auto-34Y16629

Global Exosome Therapeutics and Diagnostics Market Research Report 2024

BUY CHAPTERS

Global Exosome Therapeutics and Diagnostics Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-34Y16629

Report

November 2025

Pages:171

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Evox Therapeutics

Carmine Therapeutics

Exopharm

Aruna Bio

Capricor Therapeutics

ReNeuron

Aegle Therapeutics

Sarepta Therapeutics

Codiak BioSciences

Exosomics

Aethlon Medical

ExoCoBio

ORGANICELL

PureTech

Exosome Diagnostics

Mantra Bio

Adipomics

Innocan Pharma

Versatope

Vesvigen Therapeutics

Exosome Plus

ECHO Biaotech

Exosome Therapeutics and Diagnostics Market

The global Exosome Therapeutics and Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.

Exosomes are small vesicles secreted by cells, which contain biomolecules such as proteins, nucleic acids, and lipids. In recent years, exosomes have attracted much attention due to their role in intercellular communication, disease occurrence and development, etc. The application of exosomes in treatment and diagnosis has also gradually attracted attention.

From a downstream perspective, Cancer accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Exosome Therapeutics and Diagnostics leading manufacturers including Evox Therapeutics, Carmine Therapeutics, Exopharm, Aruna Bio, Capricor Therapeutics, Mantra Bio, Adipomics, ReNeuron, Aegle Therapeutics, Sarepta Therapeutics, etc., dominate supply; the top five capture approximately % of global revenue, with Evox Therapeutics leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Exosome Therapeutics and Diagnostics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Exosome Therapeutics and Diagnostics Market Report

Report Metric	Details
Report Name	Exosome Therapeutics and Diagnostics Market
Segment by Type	Treatment Diagnosis
Segment by Application	Cancer Neurological Diseases Others
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Evox Therapeutics, Carmine Therapeutics, Exopharm, Aruna Bio, Capricor Therapeutics, Mantra Bio, Adipomics, ReNeuron, Aegle Therapeutics, Sarepta Therapeutics, Codiak Biosciences, Exosomics, Innocan Pharma, Aethlon Medical, ExoCoBio, Organicell, Puretech, Versatope, Vesvigen Therapeutics, Exosome Plus, Exosome Diagnostics, ECHO Biaotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Exosome Therapeutics and Diagnostics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Exosome Therapeutics and Diagnostics Market report?

Ans: The main players in the Exosome Therapeutics and Diagnostics Market are Evox Therapeutics, Carmine Therapeutics, Exopharm, Aruna Bio, Capricor Therapeutics, Mantra Bio, Adipomics, ReNeuron, Aegle Therapeutics, Sarepta Therapeutics, Codiak Biosciences, Exosomics, Innocan Pharma, Aethlon Medical, ExoCoBio, Organicell, Puretech, Versatope, Vesvigen Therapeutics, Exosome Plus, Exosome Diagnostics, ECHO Biaotech

What are the Application segmentation covered in the Exosome Therapeutics and Diagnostics Market report?

Ans: The Applications covered in the Exosome Therapeutics and Diagnostics Market report are Cancer, Neurological Diseases, Others

What are the Type segmentation covered in the Exosome Therapeutics and Diagnostics Market report?

Ans: The Types covered in the Exosome Therapeutics and Diagnostics Market report are Treatment, Diagnosis

1 Study Coverage

1.1 Introduction to Exosome Therapeutics and Diagnostics: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Exosome Therapeutics and Diagnostics Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Treatment

1.2.3 Diagnosis

1.3 Market Segmentation by Application

1.3.1 Global Exosome Therapeutics and Diagnostics Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Cancer

1.3.3 Neurological Diseases

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Exosome Therapeutics and Diagnostics Revenue Estimates and Forecasts 2020-2031

2.2 Global Exosome Therapeutics and Diagnostics Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020-2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

3.1 Global Exosome Therapeutics and Diagnostics Player Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2020-2025)

3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Player (2020 VS 2024)

3.2 Global Exosome Therapeutics and Diagnostics Companies Headquarters and Service Footprint

3.3 Main Product Type Market Size by Players

3.3.1 Treatment Market Size by Players

3.3.2 Diagnosis Market Size by Players

3.4 Global Exosome Therapeutics and Diagnostics Market Concentration and Dynamics

3.4.1 Global Market Concentration (CR5 and HHI)

3.4.2 Entrant/Exit Impact Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Exosome Therapeutics and Diagnostics Revenue Trends by Type

4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.1.2 Global Revenue Market Share by Type (2020-2031)

4.2 Key Product Attributes and Differentiation

4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.3.1 High-Growth Niches and Adoption Drivers

4.3.2 Profitability Hotspots and Cost Drivers

4.3.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Exosome Therapeutics and Diagnostics Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.1.2 Revenue Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2020-2031)

6.2 North America Key Players Revenue in 2024

6.3 North America Exosome Therapeutics and Diagnostics Market Size by Type (2020-2031)

6.4 North America Exosome Therapeutics and Diagnostics Market Size by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Exosome Therapeutics and Diagnostics Market Size by Country

6.6.1 North America Revenue Trends by Country

6.6.2 US

6.6.3 Canada

6.6.4 Mexico

7 Europe

7.1 Europe Market Size (2020-2031)

7.2 Europe Key Players Revenue in 2024

7.3 Europe Exosome Therapeutics and Diagnostics Market Size by Type (2020-2031)

7.4 Europe Exosome Therapeutics and Diagnostics Market Size by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Exosome Therapeutics and Diagnostics Market Size by Country

7.6.1 Europe Revenue Trends by Country

7.6.2 Germany

7.6.3 France

7.6.4 U.K.

7.6.5 Italy

7.6.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2020-2031)

8.2 Asia-Pacific Key Players Revenue in 2024

8.3 Asia-Pacific Exosome Therapeutics and Diagnostics Market Size by Type (2020-2031)

8.4 Asia-Pacific Exosome Therapeutics and Diagnostics Market Size by Application (2020-2031)

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Asia-Pacific Exosome Therapeutics and Diagnostics Market Size by Region

8.6.1 Asia-Pacific Revenue Trends by Region

8.7 China

8.8 Japan

8.9 South Korea

8.10 Australia

8.11 India

8.12 Southeast Asia

8.12.1 Indonesia

8.12.2 Vietnam

8.12.3 Malaysia

8.12.4 Philippines

8.12.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2020-2031)

9.2 Central and South America Key Players Revenue in 2024

9.3 Central and South America Exosome Therapeutics and Diagnostics Market Size by Type (2020-2031)

9.4 Central and South America Exosome Therapeutics and Diagnostics Market Size by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Exosome Therapeutics and Diagnostics Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2020-2031)

10.2 Middle East and Africa Key Players Revenue in 2024

10.3 Middle East and Africa Exosome Therapeutics and Diagnostics Market Size by Type (2020-2031)

10.4 Middle East and Africa Exosome Therapeutics and Diagnostics Market Size by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Exosome Therapeutics and Diagnostics Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Israel

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Evox Therapeutics

11.1.1 Evox Therapeutics Corporation Information

11.1.2 Evox Therapeutics Business Overview

11.1.3 Evox Therapeutics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.1.4 Evox Therapeutics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.1.5 Evox Therapeutics Exosome Therapeutics and Diagnostics Revenue by Product in 2024

11.1.6 Evox Therapeutics Exosome Therapeutics and Diagnostics Revenue by Application in 2024

11.1.7 Evox Therapeutics Exosome Therapeutics and Diagnostics Revenue by Geographic Area in 2024

11.1.8 Evox Therapeutics Exosome Therapeutics and Diagnostics SWOT Analysis

11.1.9 Evox Therapeutics Recent Developments

11.2 Carmine Therapeutics

11.2.1 Carmine Therapeutics Corporation Information

11.2.2 Carmine Therapeutics Business Overview

11.2.3 Carmine Therapeutics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.2.4 Carmine Therapeutics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.2.5 Carmine Therapeutics Exosome Therapeutics and Diagnostics Revenue by Product in 2024

11.2.6 Carmine Therapeutics Exosome Therapeutics and Diagnostics Revenue by Application in 2024

11.2.7 Carmine Therapeutics Exosome Therapeutics and Diagnostics Revenue by Geographic Area in 2024

11.2.8 Carmine Therapeutics Exosome Therapeutics and Diagnostics SWOT Analysis

11.2.9 Carmine Therapeutics Recent Developments

11.3 Exopharm

11.3.1 Exopharm Corporation Information

11.3.2 Exopharm Business Overview

11.3.3 Exopharm Exosome Therapeutics and Diagnostics Product Features and Attributes

11.3.4 Exopharm Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.3.5 Exopharm Exosome Therapeutics and Diagnostics Revenue by Product in 2024

11.3.6 Exopharm Exosome Therapeutics and Diagnostics Revenue by Application in 2024

11.3.7 Exopharm Exosome Therapeutics and Diagnostics Revenue by Geographic Area in 2024

11.3.8 Exopharm Exosome Therapeutics and Diagnostics SWOT Analysis

11.3.9 Exopharm Recent Developments

11.4 Aruna Bio

11.4.1 Aruna Bio Corporation Information

11.4.2 Aruna Bio Business Overview

11.4.3 Aruna Bio Exosome Therapeutics and Diagnostics Product Features and Attributes

11.4.4 Aruna Bio Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.4.5 Aruna Bio Exosome Therapeutics and Diagnostics Revenue by Product in 2024

11.4.6 Aruna Bio Exosome Therapeutics and Diagnostics Revenue by Application in 2024

11.4.7 Aruna Bio Exosome Therapeutics and Diagnostics Revenue by Geographic Area in 2024

11.4.8 Aruna Bio Exosome Therapeutics and Diagnostics SWOT Analysis

11.4.9 Aruna Bio Recent Developments

11.5 Capricor Therapeutics

11.5.1 Capricor Therapeutics Corporation Information

11.5.2 Capricor Therapeutics Business Overview

11.5.3 Capricor Therapeutics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.5.4 Capricor Therapeutics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.5.5 Capricor Therapeutics Exosome Therapeutics and Diagnostics Revenue by Product in 2024

11.5.6 Capricor Therapeutics Exosome Therapeutics and Diagnostics Revenue by Application in 2024

11.5.7 Capricor Therapeutics Exosome Therapeutics and Diagnostics Revenue by Geographic Area in 2024

11.5.8 Capricor Therapeutics Exosome Therapeutics and Diagnostics SWOT Analysis

11.5.9 Capricor Therapeutics Recent Developments

11.6 Mantra Bio

11.6.1 Mantra Bio Corporation Information

11.6.2 Mantra Bio Business Overview

11.6.3 Mantra Bio Exosome Therapeutics and Diagnostics Product Features and Attributes

11.6.4 Mantra Bio Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.6.5 Mantra Bio Recent Developments

11.7 Adipomics

11.7.1 Adipomics Corporation Information

11.7.2 Adipomics Business Overview

11.7.3 Adipomics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.7.4 Adipomics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.7.5 Adipomics Recent Developments

11.8 ReNeuron

11.8.1 ReNeuron Corporation Information

11.8.2 ReNeuron Business Overview

11.8.3 ReNeuron Exosome Therapeutics and Diagnostics Product Features and Attributes

11.8.4 ReNeuron Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.8.5 ReNeuron Recent Developments

11.9 Aegle Therapeutics

11.9.1 Aegle Therapeutics Corporation Information

11.9.2 Aegle Therapeutics Business Overview

11.9.3 Aegle Therapeutics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.9.4 Aegle Therapeutics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.9.5 Aegle Therapeutics Recent Developments

11.10 Sarepta Therapeutics

11.10.1 Sarepta Therapeutics Corporation Information

11.10.2 Sarepta Therapeutics Business Overview

11.10.3 Sarepta Therapeutics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.10.4 Sarepta Therapeutics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.10.5 Company Ten Recent Developments

11.11 Codiak Biosciences

11.11.1 Codiak Biosciences Corporation Information

11.11.2 Codiak Biosciences Business Overview

11.11.3 Codiak Biosciences Exosome Therapeutics and Diagnostics Product Features and Attributes

11.11.4 Codiak Biosciences Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.11.5 Codiak Biosciences Recent Developments

11.12 Exosomics

11.12.1 Exosomics Corporation Information

11.12.2 Exosomics Business Overview

11.12.3 Exosomics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.12.4 Exosomics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.12.5 Exosomics Recent Developments

11.13 Innocan Pharma

11.13.1 Innocan Pharma Corporation Information

11.13.2 Innocan Pharma Business Overview

11.13.3 Innocan Pharma Exosome Therapeutics and Diagnostics Product Features and Attributes

11.13.4 Innocan Pharma Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.13.5 Innocan Pharma Recent Developments

11.14 Aethlon Medical

11.14.1 Aethlon Medical Corporation Information

11.14.2 Aethlon Medical Business Overview

11.14.3 Aethlon Medical Exosome Therapeutics and Diagnostics Product Features and Attributes

11.14.4 Aethlon Medical Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.14.5 Aethlon Medical Recent Developments

11.15 ExoCoBio

11.15.1 ExoCoBio Corporation Information

11.15.2 ExoCoBio Business Overview

11.15.3 ExoCoBio Exosome Therapeutics and Diagnostics Product Features and Attributes

11.15.4 ExoCoBio Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.15.5 ExoCoBio Recent Developments

11.16 Organicell

11.16.1 Organicell Corporation Information

11.16.2 Organicell Business Overview

11.16.3 Organicell Exosome Therapeutics and Diagnostics Product Features and Attributes

11.16.4 Organicell Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.16.5 Organicell Recent Developments

11.17 Puretech

11.17.1 Puretech Corporation Information

11.17.2 Puretech Business Overview

11.17.3 Puretech Exosome Therapeutics and Diagnostics Product Features and Attributes

11.17.4 Puretech Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.17.5 Puretech Recent Developments

11.18 Versatope

11.18.1 Versatope Corporation Information

11.18.2 Versatope Business Overview

11.18.3 Versatope Exosome Therapeutics and Diagnostics Product Features and Attributes

11.18.4 Versatope Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.18.5 Versatope Recent Developments

11.19 Vesvigen Therapeutics

11.19.1 Vesvigen Therapeutics Corporation Information

11.19.2 Vesvigen Therapeutics Business Overview

11.19.3 Vesvigen Therapeutics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.19.4 Vesvigen Therapeutics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.19.5 Vesvigen Therapeutics Recent Developments

11.20 Exosome Plus

11.20.1 Exosome Plus Corporation Information

11.20.2 Exosome Plus Business Overview

11.20.3 Exosome Plus Exosome Therapeutics and Diagnostics Product Features and Attributes

11.20.4 Exosome Plus Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.20.5 Exosome Plus Recent Developments

11.21 Exosome Diagnostics

11.21.1 Exosome Diagnostics Corporation Information

11.21.2 Exosome Diagnostics Business Overview

11.21.3 Exosome Diagnostics Exosome Therapeutics and Diagnostics Product Features and Attributes

11.21.4 Exosome Diagnostics Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.21.5 Exosome Diagnostics Recent Developments

11.22 ECHO Biaotech

11.22.1 ECHO Biaotech Corporation Information

11.22.2 ECHO Biaotech Business Overview

11.22.3 ECHO Biaotech Exosome Therapeutics and Diagnostics Product Features and Attributes

11.22.4 ECHO Biaotech Exosome Therapeutics and Diagnostics Revenue and Gross Margin (2020-2025)

11.22.5 ECHO Biaotech Recent Developments

12 Exosome Therapeutics and DiagnosticsIndustry Chain Analysis

12.1 Exosome Therapeutics and Diagnostics Industry Chain

12.2 Upstream Analysis

12.2.1 Upstream Key Suppliers

12.3 Middlestream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Exosome Therapeutics and Diagnostics Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Exosome Therapeutics and Diagnostics Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Evox Therapeutics

Carmine Therapeutics

Exopharm

Aruna Bio

Capricor Therapeutics

ReNeuron

Aegle Therapeutics

Sarepta Therapeutics

Codiak BioSciences

Exosomics

Aethlon Medical

ExoCoBio

ORGANICELL

PureTech

Exosome Diagnostics

Mantra Bio

Adipomics

Innocan Pharma

Versatope

Vesvigen Therapeutics

Exosome Plus

ECHO Biaotech

List of Tables

Table 1. Global Exosome Therapeutics and Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Exosome Therapeutics and Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Exosome Therapeutics and Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Exosome Therapeutics and Diagnostics Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Exosome Therapeutics and Diagnostics Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Exosome Therapeutics and Diagnostics Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Exosome Therapeutics and Diagnostics Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Exosome Therapeutics and Diagnostics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Exosome Therapeutics and Diagnostics as of 2024)

Table 11. Global Exosome Therapeutics and Diagnostics Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Exosome Therapeutics and Diagnostics Companies Headquarters

Table 13. Global Exosome Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Exosome Therapeutics and Diagnostics Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Exosome Therapeutics and Diagnostics Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Exosome Therapeutics and Diagnostics Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Exosome Therapeutics and Diagnostics Revenue by Application (2026-2031) & (US$ Million)

Table 21. Exosome Therapeutics and Diagnostics High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Exosome Therapeutics and Diagnostics Growth Accelerators and Market Barriers

Table 25. North America Exosome Therapeutics and Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Exosome Therapeutics and Diagnostics Growth Accelerators and Market Barriers

Table 27. Europe Exosome Therapeutics and Diagnostics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Exosome Therapeutics and Diagnostics Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Exosome Therapeutics and Diagnostics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Exosome Therapeutics and Diagnostics Investment Opportunities and Key Challenges

Table 31. Central and South America Exosome Therapeutics and Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Exosome Therapeutics and Diagnostics Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Exosome Therapeutics and Diagnostics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Evox Therapeutics Corporation Information

Table 35. Evox Therapeutics Description and Major Businesses

Table 36. Evox Therapeutics Product Features and Attributes

Table 37. Evox Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Evox Therapeutics Revenue Proportion by Product in 2024

Table 39. Evox Therapeutics Revenue Proportion by Application in 2024

Table 40. Evox Therapeutics Revenue Proportion by Geographic Area in 2024

Table 41. Evox Therapeutics Exosome Therapeutics and Diagnostics SWOT Analysis

Table 42. Evox Therapeutics Recent Developments

Table 43. Carmine Therapeutics Corporation Information

Table 44. Carmine Therapeutics Description and Major Businesses

Table 45. Carmine Therapeutics Product Features and Attributes

Table 46. Carmine Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Carmine Therapeutics Revenue Proportion by Product in 2024

Table 48. Carmine Therapeutics Revenue Proportion by Application in 2024

Table 49. Carmine Therapeutics Revenue Proportion by Geographic Area in 2024

Table 50. Carmine Therapeutics Exosome Therapeutics and Diagnostics SWOT Analysis

Table 51. Carmine Therapeutics Recent Developments

Table 52. Exopharm Corporation Information

Table 53. Exopharm Description and Major Businesses

Table 54. Exopharm Product Features and Attributes

Table 55. Exopharm Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Exopharm Revenue Proportion by Product in 2024

Table 57. Exopharm Revenue Proportion by Application in 2024

Table 58. Exopharm Revenue Proportion by Geographic Area in 2024

Table 59. Exopharm Exosome Therapeutics and Diagnostics SWOT Analysis

Table 60. Exopharm Recent Developments

Table 61. Aruna Bio Corporation Information

Table 62. Aruna Bio Description and Major Businesses

Table 63. Aruna Bio Product Features and Attributes

Table 64. Aruna Bio Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. Aruna Bio Revenue Proportion by Product in 2024

Table 66. Aruna Bio Revenue Proportion by Application in 2024

Table 67. Aruna Bio Revenue Proportion by Geographic Area in 2024

Table 68. Aruna Bio Exosome Therapeutics and Diagnostics SWOT Analysis

Table 69. Aruna Bio Recent Developments

Table 70. Capricor Therapeutics Corporation Information

Table 71. Capricor Therapeutics Description and Major Businesses

Table 72. Capricor Therapeutics Product Features and Attributes

Table 73. Capricor Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Capricor Therapeutics Revenue Proportion by Product in 2024

Table 75. Capricor Therapeutics Revenue Proportion by Application in 2024

Table 76. Capricor Therapeutics Revenue Proportion by Geographic Area in 2024

Table 77. Capricor Therapeutics Exosome Therapeutics and Diagnostics SWOT Analysis

Table 78. Capricor Therapeutics Recent Developments

Table 79. Mantra Bio Corporation Information

Table 80. Mantra Bio Description and Major Businesses

Table 81. Mantra Bio Product Features and Attributes

Table 82. Mantra Bio Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. Mantra Bio Recent Developments

Table 84. Adipomics Corporation Information

Table 85. Adipomics Description and Major Businesses

Table 86. Adipomics Product Features and Attributes

Table 87. Adipomics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. Adipomics Recent Developments

Table 89. ReNeuron Corporation Information

Table 90. ReNeuron Description and Major Businesses

Table 91. ReNeuron Product Features and Attributes

Table 92. ReNeuron Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. ReNeuron Recent Developments

Table 94. Aegle Therapeutics Corporation Information

Table 95. Aegle Therapeutics Description and Major Businesses

Table 96. Aegle Therapeutics Product Features and Attributes

Table 97. Aegle Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Aegle Therapeutics Recent Developments

Table 99. Sarepta Therapeutics Corporation Information

Table 100. Sarepta Therapeutics Description and Major Businesses

Table 101. Sarepta Therapeutics Product Features and Attributes

Table 102. Sarepta Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. Sarepta Therapeutics Recent Developments

Table 104. Codiak Biosciences Corporation Information

Table 105. Codiak Biosciences Description and Major Businesses

Table 106. Codiak Biosciences Product Features and Attributes

Table 107. Codiak Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. Codiak Biosciences Recent Developments

Table 109. Exosomics Corporation Information

Table 110. Exosomics Description and Major Businesses

Table 111. Exosomics Product Features and Attributes

Table 112. Exosomics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 113. Exosomics Recent Developments

Table 114. Innocan Pharma Corporation Information

Table 115. Innocan Pharma Description and Major Businesses

Table 116. Innocan Pharma Product Features and Attributes

Table 117. Innocan Pharma Revenue (US$ Million) and Gross Margin (2020-2025)

Table 118. Innocan Pharma Recent Developments

Table 119. Aethlon Medical Corporation Information

Table 120. Aethlon Medical Description and Major Businesses

Table 121. Aethlon Medical Product Features and Attributes

Table 122. Aethlon Medical Revenue (US$ Million) and Gross Margin (2020-2025)

Table 123. Aethlon Medical Recent Developments

Table 124. ExoCoBio Corporation Information

Table 125. ExoCoBio Description and Major Businesses

Table 126. ExoCoBio Product Features and Attributes

Table 127. ExoCoBio Revenue (US$ Million) and Gross Margin (2020-2025)

Table 128. ExoCoBio Recent Developments

Table 129. Organicell Corporation Information

Table 130. Organicell Description and Major Businesses

Table 131. Organicell Product Features and Attributes

Table 132. Organicell Revenue (US$ Million) and Gross Margin (2020-2025)

Table 133. Organicell Recent Developments

Table 134. Puretech Corporation Information

Table 135. Puretech Description and Major Businesses

Table 136. Puretech Product Features and Attributes

Table 137. Puretech Revenue (US$ Million) and Gross Margin (2020-2025)

Table 138. Puretech Recent Developments

Table 139. Versatope Corporation Information

Table 140. Versatope Description and Major Businesses

Table 141. Versatope Product Features and Attributes

Table 142. Versatope Revenue (US$ Million) and Gross Margin (2020-2025)

Table 143. Versatope Recent Developments

Table 144. Vesvigen Therapeutics Corporation Information

Table 145. Vesvigen Therapeutics Description and Major Businesses

Table 146. Vesvigen Therapeutics Product Features and Attributes

Table 147. Vesvigen Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 148. Vesvigen Therapeutics Recent Developments

Table 149. Exosome Plus Corporation Information

Table 150. Exosome Plus Description and Major Businesses

Table 151. Exosome Plus Product Features and Attributes

Table 152. Exosome Plus Revenue (US$ Million) and Gross Margin (2020-2025)

Table 153. Exosome Plus Recent Developments

Table 154. Exosome Diagnostics Corporation Information

Table 155. Exosome Diagnostics Description and Major Businesses

Table 156. Exosome Diagnostics Product Features and Attributes

Table 157. Exosome Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 158. Exosome Diagnostics Recent Developments

Table 159. ECHO Biaotech Corporation Information

Table 160. ECHO Biaotech Description and Major Businesses

Table 161. ECHO Biaotech Product Features and Attributes

Table 162. ECHO Biaotech Revenue (US$ Million) and Gross Margin (2020-2025)

Table 163. ECHO Biaotech Recent Developments

Table 164. Raw Materials Key Suppliers

Table 165. Distributors List

Table 166. Market Trends and Market Evolution

Table 167. Market Drivers and Opportunities

Table 168. Market Challenges, Risks, and Restraints

Table 169. Research Programs/Design for This Report

Table 170. Key Data Information from Secondary Sources

Table 171. Key Data Information from Primary Sources

List of Figures

Figure 1. Exosome Therapeutics and Diagnostics Product Picture

Figure 2. Global Exosome Therapeutics and Diagnostics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Treatment Product Picture

Figure 4. Diagnosis Product Picture

Figure 5. Global Exosome Therapeutics and Diagnostics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Cancer

Figure 7. Neurological Diseases

Figure 8. Others

Figure 9. Exosome Therapeutics and Diagnostics Report Years Considered

Figure 10. Global Exosome Therapeutics and Diagnostics Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 12. Global Exosome Therapeutics and Diagnostics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Exosome Therapeutics and Diagnostics Revenue Market Share by Region (2020-2031)

Figure 14. Global Exosome Therapeutics and Diagnostics Revenue Market Share Ranking (2024)

Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 16. Treatment Revenue Market Share by Player in 2024

Figure 17. Diagnosis Revenue Market Share by Player in 2024

Figure 18. Global Exosome Therapeutics and Diagnostics Revenue Market Share by Type (2020-2031)

Figure 19. Global Exosome Therapeutics and Diagnostics Revenue Market Share by Application (2020-2031)

Figure 20. North America Exosome Therapeutics and Diagnostics Revenue YoY (2020-2031) & (US$ Million)

Figure 21. North America Top 5 Players Exosome Therapeutics and Diagnostics Revenue (US$ Million) in 2024

Figure 22. North America Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Type (2020 - 2031)

Figure 23. North America Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Application (2020-2031)

Figure 24. US Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 25. Canada Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 26. Mexico Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 27. Europe Exosome Therapeutics and Diagnostics Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Europe Top 5 Players Exosome Therapeutics and Diagnostics Revenue (US$ Million) in 2024

Figure 29. Europe Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Type (2020-2031)

Figure 30. Europe Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Application (2020-2031)

Figure 31. Germany Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 32. France Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 33. U.K. Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 34. Italy Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 35. Russia Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Exosome Therapeutics and Diagnostics Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Top 8 Players Exosome Therapeutics and Diagnostics Revenue (US$ Million) in 2024

Figure 38. Asia-Pacific Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Type (2020-2031)

Figure 39. Asia-Pacific Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Application (2020-2031)

Figure 40. Indonesia Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 41. Japan Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 42. South Korea Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 43. Australia Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 44. India Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 45. Indonesia Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 46. Vietnam Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 47. Malaysia Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 48. Philippines Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 49. Singapore Exosome Therapeutics and Diagnostics Revenue (2020-2031) & (US$ Million)

Figure 50. Central and South America Exosome Therapeutics and Diagnostics Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Central and South America Top 5 Players Exosome Therapeutics and Diagnostics Revenue (US$ Million) in 2024

Figure 52. Central and South America Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Type (2020-2031)

Figure 53. Central and South America Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Application (2020-2031)

Figure 54. Brazil Exosome Therapeutics and Diagnostics Revenue (2020-2025) & (US$ Million)

Figure 55. Argentina Exosome Therapeutics and Diagnostics Revenue (2020-2025) & (US$ Million)

Figure 56. Middle East and Africa Exosome Therapeutics and Diagnostics Revenue YoY (2020-2031) & (US$ Million)

Figure 57. Middle East and Africa Top 5 Players Exosome Therapeutics and Diagnostics Revenue (US$ Million) in 2024

Figure 58. South America Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Type (2020-2031)

Figure 59. Middle East and Africa Exosome Therapeutics and Diagnostics Revenue (US$ Million) by Application (2020-2031)

Figure 60. GCC Countries Exosome Therapeutics and Diagnostics Revenue (2020-2025) & (US$ Million)

Figure 61. Israel Exosome Therapeutics and Diagnostics Revenue (2020-2025) & (US$ Million)

Figure 62. Egypt Exosome Therapeutics and Diagnostics Revenue (2020-2025) & (US$ Million)

Figure 63. South Africa Exosome Therapeutics and Diagnostics Revenue (2020-2025) & (US$ Million)

Figure 64. Exosome Therapeutics and Diagnostics Industry Chain Mapping

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Exosome Diagnostic and Therapeutic Market Insights Forecast to 2030

Global Exosome Technology Services Market Research Report 2025

Global Exosome Research Market Research Report 2024

Global Msenchymal Stem Cell and Exosome Diagnostics and Therapies Market Research Report 2025

Global Medicinal Exosomes Market Research Report 2024

Diagnostic Exosome Biomarker Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Extracellular Vesicle Therapy Market Research Report 2024

Global Exosome Therapeutics Market Research Report 2024

Global Exosome Manufacturing Service Market Research Report 2024

Global Exosome Therapy Technology Market Research Report 2025

Global Exosome Rapid Molecular Detection Market Research Report 2024

Global Exosomes Skincare Market Research Report 2025

Global Plant Exosomes Market Research Report 2025

Global Exosome Technologies Market Research Report 2025

Global Exosome Isolation Kits Market Research Report 2025

Global Milk Exosomes Market Research Report 2024

Global Exosome Service Market Research Report 2025

Global Exosome Therapy Market Research Report 2025

Global Exosome Medical Technology Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions